UROONCO BCa chief editor Dr. Benjamin Pradere (FR) interviews Dr. Bogdana Schmidt (US) about her research on the real-world outcomes of reinduction with nadofaragene firadenovec in patients with Bacillus Calmette-Guerin (BCG)-unresponsive NMIBC. Nadofaragene firadenovec is the first Food and Drug Administration-approved intravesical gene therapy for BCG-unresponsive NMIBC.
Dr. Bogdana talks about the study design, the patient profiles of the reintroduction, the real-world data and how the results could impact clinical practice.
Publication references: Schmidt B, Horns JJ, Tyson MD, Daneshmand S, Linehan JA, Agarwal PK, Narayan VM, Dickstein R, Luckenbaugh AN, Lotan Y. Outcomes of reinduction with nadofaragene firadenovec. J Urol. 2025;214(5):472-473 https://www.auajournals.org/doi/10.1097/JU.0000000000004697
ABLE 22 Study: A Phase III trial to evaluate intravesical nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy in participants with high-grade BCG unresponsive non-muscle invasive bladder cancer. ClinicalTrials.gov ID: NCT06545955. https://clinicaltrials.gov/study/NCT06545955